PSMD1-score | 1 (n=26) | 2 (n=27) | 3 (n=39) |
---|---|---|---|
Age (years) mean | 63.4 | 60.8 | 60.2 |
Q1/Q2/Q3 | 58.5/64/70.2 | 52/60/70 | 51/61/68 |
Male (%) | 88.4 | 81.4 | 73.6 |
Weight (kg) mean | 64.9 | 68.8 | 67.7 |
Q1/Q2/Q3 | 57.8/64.5/73 | 56.8/68.8/77.5 | 57.8/68.7/77.6 |
Smoker (n) | 7/26 | 17/26 | 17/39 |
Karnofski >= 70% (n) | 19/19 | 19/20 | 30/30 |
Hemoglobin level (mg/dL) mean | 12.7 | 12.7 | 12.0 |
Q1/Q2/Q3 | 12.0/12.6/13.6 | 11.1/13.1/14 | 11.2/11.9/12.9 |
Unknown primary | Â | 1 (3.7) | Â |
Oral cavity n (%) | 7 (26.9) | 8 (29.6) | 9 (23.0) |
Oropharynx n (%) | 9 (34.6) | 10 (37.0) | 16 ( 41.0) |
Hypopharynx n (%) | 5 (19.2) | 2 (7.4) | 8 (20.5) |
Larynx n (%) | 5 (19.2) | 6 (22.2) | 6 (15.3) |
cT0 n (%) | Â | 1 (3.8) | 3 (7.6) |
cT1 n (%) | 7 (26.9) | 2 (7.6) | 7 (17.9) |
cT2 n (%) | 8 (30.7) | 8 (30.7) | 11 (28.2) |
cT3 n (%) | 6 (23.0) | 6 (23.0) | 11 (28.2) |
cT4 n (%) | 5 (19.2) | 9 (34.6) | 7 (17.9) |
cN0 n (%) | 2 (7.6) | 6 (22.2) | 5 (12.8) |
cN1 n (%) | 5 (19.2) | 4 (14.8) | 14 (35.8) |
cN2 n (%) | 18 (69.2) | 14 (51.8) | 19 (48.6) |
cN3 n (%) | 1 (3.8) | 3 (11.1) | 1 (2.5) |
G1 n (%) | Â | 1 (3.7) | 1 (2.5) |
G2 n (%) | 12 (46.1) | 15 (55.5) | 21 (53.8) |
G3 n (%) | 14 (53.8) | 11 (40.7) | 17 (43.5) |
EpoR (C20+) (%) | 17 (65.3) | 24 (88.8) | 26 (66.6) |
RT (Gy) mean | 62.9 | 63.9 | 62.2 |
Q1/Q2/Q3 | 60/64/64 | 63/64/66 | 60/63/64 |
RT (days) | 46.9 | 46.3 | 45.7 |
Q1/Q2/Q3 | 43/45/48 | 44/45/50 | 43.7/44.5/47.5 |
Treated in study A1/C3/D4 (n) | 3/22/1 | 6/18/3 | 4/31/4 |
Local control (months) median | nr | nr | nr |
Survival (months) median; 95% CI | 48.2; 12.4-92.6 | 29.3; 13–74.1 | 42.8; 20.7-66.2 |